Enrofloxacin Injectable solution bulk supplier for pharma manufacturers

Enrofloxacin Injectable Solution Suppliers & Bulk Manufacturers

Available Forms: Injectable solution

Available Strengths: 50 mg, 100 mg, 250 mg, and 500 mg

Reference Brands: Baytril(US & EU)

Enrofloxacin injectable works by inhibiting bacterial DNA gyrase, disrupting DNA replication and leading to bacterial cell death. It provides rapid, broad-spectrum activity against respiratory, urinary, and skin infections in animals. Benefits include quick parasite clearance, reduced disease transmission, and improved animal health and productivity when used properly under veterinary guidance.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Enrofloxacin injectable formulations are approved in the US and EU, supported by dossiers demonstrating safety, efficacy, and quality in line with GMP standards. In the US, FDA approval involves rigorous clinical data, while in the EU, CE marking certifies compliance with veterinary medicinal product regulations. These products undergo validation, stability testing, and comprehensive audits, with detailed documentation including safety profiles, clinical trial outcomes, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to safe, effective enrofloxacin injectable formulations critical for treating bacterial infections in animals worldwide, supporting animal health and productivity.

Enrofloxacin Injectable Solution — third party manufacturing & bulk supply

Enrofloxacin Injectable Solution is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Enrofloxacin Injectable Solution is supplied as Injectable solution — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Enrofloxacin Injectable Solution listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Enrofloxacin Injectable Solution →

Back to Listing

Frequently Asked Questions

Enrofloxacin injection is used for the treatment of bacterial infections in animals caused by susceptible Gram-negative and some Gram-positive organisms. It is commonly prescribed for respiratory infections, urinary tract infections, gastrointestinal infections, septicemia, and skin and soft tissue infections.

Enrofloxacin injection is made from enrofloxacin, a fluoroquinolone antibiotic that works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair, leading to bacterial cell death.

Common trade names include Baytril Injectable, Enrovet, Enroflox Injection, and other veterinary formulations.

Enrofloxacin injection is manufactured by multiple veterinary pharmaceutical companies globally, including Bayer (Baytril), Zoetis, Intas Pharmaceuticals, Virbac, and other generic manufacturers.

The generic name is enrofloxacin injection.

Brand names include Baytril Injectable, Enrovet, Enroflox Injection, and other region-specific veterinary brands.

Enrofloxacin injection is manufactured worldwide, with major production in India, Europe, and the United States by veterinary-focused pharmaceutical companies.